The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

A biopsy reveals squamous cell carcinoma (SCC) in situ ... completely before undertaking surgical removal of the lesion. Two stages of Mohs surgery were required to clear the tumor, which involved ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Mohs surgery significantly improved recurrence, metastasis, and mortality rates in patients with primary high-stage cutaneous ...

KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Expression of tissue factor (TF) in penile squamous cell carcinoma (PSCC) and enrichment in HPV-negative cases. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...